Stemline Therapeutics Inc (STML.O)

STML.O on Consolidated Issue listed on NASDAQ Capital Market

12.78USD
31 Jul 2014
Price Change (% chg)

$-0.90 (-6.58%)
Prev Close
$13.68
Open
$13.46
Day's High
$13.50
Day's Low
$12.58
Volume
102,918
Avg. Vol
133,544
52-wk High
$47.25
52-wk Low
$10.68

STML.O

Chart for STML.O

About

Stemline Therapeutics, Inc. (Stemline) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds... (more)

Overall

Beta: --
Market Cap (Mil.): $181.18
Shares Outstanding (Mil.): 13.24
Dividend: --
Yield (%): --

Financials

  STML.O Industry Sector
P/E (TTM): -- 107.05 36.29
EPS (TTM): -2.30 -- --
ROI: -54.76 -0.60 18.13
ROE: -55.39 -1.65 18.95
Search Stocks

Competitors

  Price Change
Astellas Pharma Inc (4503.T) ¥1,416 +0.50
Eisai Co., Ltd (4523.T) ¥4,404 +5.50
Sumitomo Dainippon Pharma Co Ltd (4506.T) ¥1,268 +1.00
Pfizer Inc. (PFE.N) $28.70 -0.56
Novartis AG (NOVN.VX) CHF79.55 -0.80
Merck & Co., Inc. (MRK.N) $56.74 -1.34
Roche Holding Ltd. (ROG.VX) CHF264.70 -2.00
Sanofi SA (SASY.PA) €78.62 +1.73
GlaxoSmithKline plc (GSK.L) 1,436.50p +11.50
Amgen, Inc. (AMGN.OQ) $127.70 -2.31

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks